← Leaderboards
Ian Alexander Blair
University Of Pennsylvania
$30,276,296
Attributed
$35,830,193
Total exposure
41
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$48,613,651 · 45
By mechanism
P42$13,577,286 · 3
R01$11,229,296 · 6
U01$6,337,599 · 2
P30$5,654,253 · 7
R25$4,319,495 · 1
S10$2,967,326 · 16
Top collaborators
- Wei-Ting Hwang5 shared
- David Robinson Lynch5 shared
- Jerry D Glickson4 shared
- Andrew Strasser4 shared
- Daniel F. Heitjan2 shared
- Eldon R Jupe2 shared
- Kavindra Nath2 shared
- Richard J Santen2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Trevor M. Penning$29,812,455
- Brian D Gregory$488,449
- Andrew Strasser$14,231,368
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseBiological MarkersMonitorMethodologyResearch PersonnelOxidative StressSensitivity And SpecificityLiquid Chromatography Mass SpectrometryStable IsotopeLiquid ChromatographyHuman SubjectResolutionResearch DesignCellsSerumBiologicalAdductMetabolomicsMediatingEnvironmental ToxicologyDna DamageProteinsProgramsSampling
Grant awards (140)
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$757,387
U01 · FY2024 · NS · contact PI
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy$455,881
R01 · FY2024 · CA
Translational Biomarker Facility Core$256,557
P30 · FY2024 · ES · contact PI
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$811,272
U01 · FY2023 · NS · contact PI
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy$470,275
R01 · FY2023 · CA
Translational Biomarker Facility Core$237,790
P30 · FY2023 · ES · contact PI
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$752,008
U01 · FY2022 · NS · contact PI
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy$470,275
R01 · FY2022 · CA
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$754,041
U01 · FY2021 · NS · contact PI
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy$479,380
R01 · FY2021 · CA
Translational Biomarker Facility Core$263,533
P30 · FY2021 · ES · contact PI
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$781,493
U01 · FY2020 · NS · contact PI
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy$478,396
R01 · FY2020 · CA
Translational Biomarker Facility Core$264,706
P30 · FY2020 · ES · contact PI
Translational Biomarker Core$277,988
P30 · FY2019 · ES · contact PI
Asbestos fate, exposure, remediation, and adverse health effects$1,953,981
P42 · FY2018 · ES · contact PI
Core A - Administrative Core$313,552
P42 · FY2018 · ES · contact PI
Biomedical Project 6 - Biomarkers of Asbestos Exposure$250,677
P42 · FY2018 · ES · contact PI
Translational Biomarker Core$238,257
P30 · FY2018 · ES · contact PI
Asbestos fate, exposure, remediation, and adverse health effects$238,000
P42 · FY2018 · ES · contact PI
Translational Biomarker Core$71,455
P30 · FY2018 · ES · contact PI
Asbestos fate, exposure, remediation, and adverse health effects$2,204,665
P42 · FY2017 · ES · contact PI
Biomedical Project 6 - Biomarkers of Asbestos Exposure$279,569
P42 · FY2017 · ES · contact PI
Translational Biomarker Core$240,000
P30 · FY2017 · ES · contact PI
Core A - Administrative Core$143,655
P42 · FY2017 · ES · contact PI
Asbestos fate, exposure, remediation, and adverse health effects$49,500
P42 · FY2017 · ES · contact PI
Asbestos fate, exposure, remediation, and adverse health effects$2,253,090
P42 · FY2016 · ES · contact PI
Core N: MOLECULAR PROFILING$512,392
U54 · FY2016 · HL · contact PI
Biomedical Project 6 - Biomarkers of Asbestos Exposure$282,362
P42 · FY2016 · ES · contact PI
Translational Biomarker Core$240,000
P30 · FY2016 · ES · contact PI
Core A - Administrative Core$144,775
P42 · FY2016 · ES · contact PI
Asbestos fate, exposure, remediation, and adverse health effects$10,800
P42 · FY2016 · ES · contact PI
Asbestos fate, exposure, remediation, and adverse health effects$2,261,994
P42 · FY2015 · ES · contact PI
Core N: MOLECULAR PROFILING$511,517
U54 · FY2015 · HL · contact PI
Biomedical Project 6 - Biomarkers of Asbestos Exposure$285,214
P42 · FY2015 · ES · contact PI
Translational Biomarker Core$240,001
P30 · FY2015 · ES · contact PI
Core A - Administrative Core$146,235
P42 · FY2015 · ES · contact PI
Asbestos fate, exposure, remediation, and adverse health effects$50,000
P42 · FY2015 · ES · contact PI
Asbestos fate, exposure, remediation, and adverse health effects$2,277,765
P42 · FY2014 · ES · contact PI
Core N: MOLECULAR PROFILING$516,139
U54 · FY2014 · HL · contact PI
Biomedical Project 6 - Biomarkers of Asbestos Exposure$285,215
P42 · FY2014 · ES · contact PI
Facility/Service Cores$277,848
P30 · FY2014 · ES · contact PI
Core A - Administrative Core$146,237
P42 · FY2014 · ES · contact PI
Core N: MOLECULAR PROFILING$513,713
U54 · FY2013 · HL · contact PI
Training program in cancer pharmacology$504,858
R25 · FY2013 · CA · contact PI
Development of Breast Cancer Risk Model Based on Estrogen Metabolomics$335,808
R01 · FY2013 · CA
Facility/Service Cores$266,552
P30 · FY2013 · ES · contact PI
Biomarkers of toxic response to low nicotine cigarette smoke$560,864
R01 · FY2012 · CA · contact PI
Development of Breast Cancer Risk Model Based on Estrogen Metabolomics$442,764
R01 · FY2012 · CA
Training program in cancer pharmacology$406,325
R25 · FY2012 · CA · contact PI
Core N: MOLECULAR PROFILING$311,358
U54 · FY2012 · HL · contact PI
Facility/Service Cores$266,467
P30 · FY2012 · ES · contact PI
Biomarkers of toxic response to low nicotine cigarette smoke$562,125
R01 · FY2011 · CA · contact PI
Molecular mechanisms of DNA damage by PAHs$292,475
R01 · FY2011 · CA · contact PI
Training program in cancer pharmacology$273,906
R25 · FY2011 · CA · contact PI
Facility/Service Cores$255,626
P30 · FY2011 · ES · contact PI
Biomarkers of toxic response to low nicotine cigarette smoke$586,544
R01 · FY2010 · CA · contact PI
Exposure and biological response biomarkers of cigarette smoke$579,444
U01 · FY2010 · ES · contact PI
Training program in cancer pharmacology$525,255
R25 · FY2010 · CA · contact PI
Molecular mechanisms of DNA damage by PAHs$303,827
R01 · FY2010 · CA · contact PI
Molecular dosimetry of endogeneous genotoxins$248,790
R01 · FY2010 · CA · contact PI
Facility/Service Cores$224,131
P30 · FY2010 · ES · contact PI
Exposure and biological response biomarkers of cigarette smoke$658,708
U01 · FY2009 · ES · contact PI
Biomarkers of toxic response to low nicotine cigarette smoke$577,837
R01 · FY2009 · CA · contact PI
Training program in cancer pharmacology$524,571
R25 · FY2009 · CA · contact PI
Molecular mechanisms of DNA damage by PAHs$416,483
R01 · FY2009 · CA · contact PI
Molecular dosimetry of endogeneous genotoxins$248,790
R01 · FY2009 · CA · contact PI
CORE--Oxidative Stress and Oxidative Stress Injury$72,628
P30 · FY2009 · ES · contact PI
Exposure and biological response biomarkers of cigarette smoke$25,767
U01 · FY2009 · ES · contact PI
Exposure and biological response biomarkers of cigarette smoke$7,875
U01 · FY2009 · ES · contact PI
Exposure and biological response biomarkers of cigarette smoke$549,700
U01 · FY2008 · ES · contact PI
Molecular mechanisms of DNA damage by PAHs$406,683
R01 · FY2008 · CA · contact PI
Molecular dosimetry of endogeneous genotoxins$248,790
R01 · FY2008 · CA · contact PI
CORE--Oxidative Stress and Oxidative Stress Injury$71,712
P30 · FY2008 · ES · contact PI
Exposure and biological response biomarkers of cigarette smoke$659,904
U01 · FY2007 · ES · contact PI
Training Program in Cancer Pharmacology$487,787
R25 · FY2007 · CA · contact PI
Molecular mechanisms of DNA damage by PAHs$419,406
R01 · FY2007 · CA · contact PI
Molecular dosimetry of endogeneous genotoxins$248,790
R01 · FY2007 · CA · contact PI
CORE--Oxidative Stress and Oxidative Stress Injury$85,408
P30 · FY2007 · ES · contact PI
Training Program in Cancer Pharmacology$495,274
R25 · FY2006 · CA · contact PI
Core--Biomarker$305,661
P50 · FY2006 · HL · contact PI
Dosimetry of Lipid-Derived Amino Acid Adducts by LC/MS$275,500
R01 · FY2006 · CA · contact PI
Molecular dosimetry of endogeneous genotoxins$255,543
R01 · FY2006 · CA · contact PI
Oxidative DNA Damange and Atheroisclerosis$199,804
P50 · FY2006 · HL · contact PI
Core B-- Proteomics Core$164,719
P50 · FY2006 · HL · contact PI
CORE--Oxidative Stress and Oxidative Stress Injury$46,824
P30 · FY2006 · ES · contact PI
Training Program in Cancer Pharmacology$520,264
R25 · FY2005 · CA
High resolution triple quadrupole mass spectrometer$404,341
S10 · FY2005 · RR
Dosimetry of Lipid-Derived Amino Acid Adducts by LC/MS$282,130
R01 · FY2005 · CA
Molecular Dosimetry of Endogenous Genotoxins$263,110
R01 · FY2005 · CA
HIGH RESOLUTION TRIPLE QUADRUPOLE MASS SPECTROMETER: BIOCHEMISTRY$242,605
S10 · FY2005 · RR
Oxidative DNA Damange and Atheroisclerosis$195,181
P50 · FY2005 · HL
Core B-- Proteomics Core$160,220
P50 · FY2005 · HL
HIGH RESOLUTION TRIPLE QUADRUPOLE MASS SPECTROMETER: CARDIOVASCULAR$121,302
S10 · FY2005 · RR
HIGH RESOLUTION TRIPLE QUADRUPOLE MASS SPECTROMETER: CANCER$40,434
S10 · FY2005 · RR
Fourier Transform Mass Spec Proteomics and Genomics$771,572
S10 · FY2004 · RR
Training Program in Cancer Pharmacology$370,668
R25 · FY2004 · CA
Acquisition of a linear Q-Trap LC/MS/MS System$307,750
S10 · FY2004 · RR
Dosimetry of Lipid-Derived Amino Acid Adducts by LC/MS$282,130
R01 · FY2004 · CA
Molecular Dosimetry of Endogenous Genotoxins$263,110
R01 · FY2004 · CA
FOURIER TRANSFORM MASS SPEC PROTEOMICS AND GENOMICS: BIOCHEMISTRY$208,324
S10 · FY2004 · RR
FOURIER TRANSFORM MASS SPEC PROTEOMICS AND GENOMICS: CANCER$192,893
S10 · FY2004 · RR
Oxidative DNA Damange and Atheroisclerosis$190,692
P50 · FY2004 · HL
FOURIER TRANSFORM MASS SPEC PROTEOMICS AND GENOMICS: CARDIOVASCULAR$185,177
S10 · FY2004 · RR
Core B-- Proteomics Core$155,853
P50 · FY2004 · HL
FOURIER TRANSFORM MASS SPEC PROTEOMICS AND GENOMICS: SMOKING &TOBACCO$154,314
S10 · FY2004 · RR
ACQUISITION OF A LINEAR Q-TRAP LC/MS/MS SYSTEM: NICOTINE STUDIES$82,068
S10 · FY2004 · RR
ACQUISITION OF A LINEAR Q-TRAP LC/MS/MS SYSTEM: CARCINOGENESIS$82,067
S10 · FY2004 · RR
ACQUISITION OF A LINEAR Q-TRAP LC/MS/MS SYSTEM: ATHEROSCLEROSIS$82,065
S10 · FY2004 · RR
FOURIER TRANSFORM MASS SPEC PROTEOMICS AND GENOMICS: INFECTIOUS DISEASE$30,864
S10 · FY2004 · RR
ACQUISITION OF A LINEAR Q-TRAP LC/MS/MS SYSTEM: DIABETES$30,775
S10 · FY2004 · RR
ACQUISITION OF A LINEAR Q-TRAP LC/MS/MS SYSTEM: PROTOZOAN PARASITES$30,775
S10 · FY2004 · RR
Dosimetry of Lipid-Derived Amino Acid Adducts by LC/MS$282,130
R01 · FY2003 · CA
Molecular Dosimetry of Endogenous Genotoxins$263,110
R01 · FY2003 · CA
Training Program in Cancer Pharmacology$210,587
R25 · FY2003 · CA
Oxidative DNA Damange and Atheroisclerosis$186,335
P50 · FY2003 · HL
Core B-- Proteomics Core$151,612
P50 · FY2003 · HL
Symposium on Proteomics and Toxicology$7,908
R13 · FY2003 · ES
Dosimetry of Lipid-Derived Amino Acid Adducts by LC/MS$282,130
R01 · FY2002 · CA
Molecular Dosimetry of Endogenous Genotoxins$263,110
R01 · FY2002 · CA
CORE--CANCER PHARMACOLOGY BIOANALYTICAL FACILITY$228,564
P30 · FY2002 · CA
CORE--MASS SPECTROMETRY/ANALYTICAL CHEMISTRY$174,086
P30 · FY2002 · ES
PHARMACOKINETICS AND IMAGING$0
P01 · FY2002 · CA
Core--Proteomics$0
P50 · FY2002 · HL
Oxidative DNA damage and atherosclerosis$0
P50 · FY2002 · HL
Core--Bioanalytical$0
P01 · FY2002 · CA
Covalent modification to DNA by PAH metabolites and reactive oxygen species$0
P01 · FY2002 · CA
CORE--CANCER PHARMACOLOGY BIOANALYTICAL FACILITY$276,694
P30 · FY2001 · CA
Molecular Dosimetry of Endogenous Genotoxins$263,110
R01 · FY2001 · CA
CORE--CANCER PHARMACOLOGY BIOANALYTICAL FACILITY$228,564
P30 · FY2001 · CA
CORE--MASS SPECTROMETRY/ANALYTICAL CHEMISTRY$174,086
P30 · FY2001 · ES
CORE--ANALYTICAL LABORATORY$135,290
P50 · FY2001 · DK
CORE--ANALYTICAL LABORATORY$0
P50 · FY2001 · DK
PHARMACOKINETICS AND IMAGING$0
P01 · FY2001 · CA
CORE--CANCER PHARMACOLOGY BIOANALYTICAL FACILITY$276,694
P30 · FY2000 · CA
CORE--ANALYTICAL CORE$225,859
P50 · FY2000 · GM
CORE--MASS SPECTROMETRY/ANALYTICAL CHEMISTRY$223,996
P30 · FY2000 · ES
CORE--MASS SPECTROMETRY/ANALYTICAL CHEMISTRY$174,086
P30 · FY2000 · ES
CORE--ANALYTICAL LABORATORY$84,143
P50 · FY2000 · DK
PHARMACOKINETICS AND IMAGING$0
P01 · FY2000 · CA